In ophthalmic trials supported by 20/20 Onsite, point-of-need delivery has achieved a 9% dropout rate against a 30% Phase 3 industry benchmark, a 70% improvement in retention. Participants receiving...
Read More
In clinical trials that deal with ocular hypertension, intraocular pressure (IOP) is not just a measurement. It is often the primary determinant of regulatory credibility and treatment response...
Read More
Selecting an ophthalmology CRO is a risk decision, not just a vendor decision: sponsors are choosing how ocular endpoints will be protected across every site and visit. Most ophthalmology CROs...
Read More
Ophthalmology Clinical Trials: Strategic Growth, Scientific Innovation, and Execution Risk for Sponsors Key Takeaways Aging populations and chronic disease growth are expanding the patient pool for...
Read More
Transportation is not a soft, patient-experience issue in clinical trials. It's a protocol execution risk. When participants miss visits because getting to the site is difficult, timelines slip, data...
Read More
How to Reduce Patient Dropout Rates in Clinical Trials: Sponsor-Driven Retention Strategies That Protect Timelines Key Takeaways Dropout is a sponsor risk that impacts timelines, data continuity,...
Read More
BCVA, OCT, and IOP endpoints are rarely lost to one large failure. They're lost to small, repeated inconsistencies across sites: lighting that's "close enough," a slightly different approach to...
Read More
A decentralized clinical trial (DCT) platform is the technology stack that coordinates on-site and remote activity, connecting trial partners, vendors, and tools rather than replacing any of them....
Read More